knowledge -WSS

knowledge

author：entertainment 2025-09-29 22:48:29 - browse：4

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Why workplace violence is so common in health care

focus

WSS

To avoid data mishandling cases, universities eye AI and other tools

Medicare threatens to cut off funding for HCA's Mission hospital

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Why did Pfizer dish out millions for a Super Bowl ad?

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

23andMe had bad news about my health. I wish a person had delivered it

A disappointing year of Humira biosimilars

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

George Santos makes 1st court appearance after pleading not guilty to 13 counts

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

Anesthesiologist group: stop taking Ozempic before surgery

What we’ve learned from the Aduhelm mess

Jerome Adams on the need for new antivirals for Covid

'The Exorcist' director William Friedkin dead at 87

focus

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

What we’ve learned from the Aduhelm mess

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

'The Exorcist' director William Friedkin dead at 87

Why workplace violence is so common in health care

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

explore

focus

hotspot

knowledge